Exact Sciences Corporation (EXAS)
NASDAQ
Market Cap
$9.69B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
148 of 951
Rank in Industry
6 of 52
Largest Insider Buys in Sector
EXAS Stock Price History Chart
EXAS Stock Performance
About Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Insider Activity of Exact Sciences Corporation
Over the last 12 months, insiders at Exact Sciences Corporation have bought $1M and sold $6.35M worth of Exact Sciences Corporation stock.
On average, over the past 5 years, insiders at Exact Sciences Corporation have bought $1M and sold $24.99M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Conroy Kevin T (President and CEO) — $1M.
The last purchase of 19,500 shares for transaction amount of $1M was made by Conroy Kevin T (President and CEO) on 2024‑11‑13.
List of Insider Buy and Sell Transactions, Exact Sciences Corporation
| 2024-11-13 | President and CEO | 19,500 0.0106% | $51.35 | $1M | +15.75% | |||
| 2024-10-08 | Sale | EVP, GM, Precision Oncology | 929 0.0005% | $70.00 | $65,030 | -11.82% | ||
| 2024-09-18 | Sale | EVP, GM, Precision Oncology | 929 0.0005% | $70.00 | $65,030 | -10.87% | ||
| 2024-05-01 | Sale | President and CEO | 1,155 0.0006% | $60.15 | $69,473 | -3.89% | ||
| 2024-05-01 | Sale | EVP, Human Resources | 102 <0.0001% | $60.15 | $6,135 | -3.89% | ||
| 2024-05-01 | Sale | Chief Commercial Officer | 136 <0.0001% | $60.15 | $8,180 | -3.89% | ||
| 2024-05-01 | Sale | director | 67 <0.0001% | $60.15 | $4,030 | -3.89% | ||
| 2024-05-01 | Sale | General Manager, Screening | 102 <0.0001% | $60.15 | $6,135 | -3.89% | ||
| 2024-05-01 | Sale | EVP, GM., Precision Oncology | 110 <0.0001% | $60.15 | $6,617 | -3.89% | ||
| 2024-05-01 | Sale | Chief Financial Officer | 136 <0.0001% | $60.15 | $8,180 | -3.89% | ||
| 2024-05-01 | Sale | SVP, General Counsel & Sec | 30 <0.0001% | $60.15 | $1,805 | -3.89% | ||
| 2024-04-02 | Sale | EVP, GM., Precision Oncology | 924 0.0005% | $79.43 | $73,393 | -20.03% | ||
| 2024-04-01 | Sale | EVP, Human Resources | 2,000 0.0011% | $70.00 | $140,000 | -16.18% | ||
| 2024-03-28 | Sale | EVP, Human Resources | 2,000 0.0011% | $70.00 | $140,000 | -14.48% | ||
| 2024-03-01 | Sale | President and CEO | 8,271 0.0046% | $59.32 | $490,636 | -0.04% | ||
| 2024-03-01 | Sale | EVP, Human Resources | 1,724 0.0009% | $59.32 | $102,268 | -0.04% | ||
| 2024-03-01 | Sale | director | 2,000 0.0011% | $57.50 | $115,000 | -0.04% | ||
| 2024-03-01 | Sale | Chief Commercial Officer | 2,412 0.0013% | $59.32 | $143,080 | -0.04% | ||
| 2024-03-01 | Sale | director | 5,000 0.0027% | $57.50 | $287,500 | -0.04% | ||
| 2024-03-01 | Sale | General Manager, Screening | 2,154 0.0012% | $59.32 | $127,775 | -0.04% |
Insider Historical Profitability
64.27%
| Conroy Kevin T | President and CEO | 1074191 0.5804% | $52.33 | 7 | 72 | +71.25% |
| Condella Sarah | EVP, Human Resources | 72611 0.0392% | $52.33 | 0 | 33 | |
| Doyle James Edward | director | 50110 0.0271% | $52.33 | 1 | 12 | +138.27% |
| Cunningham Everett | Chief Commercial Officer | 47042 0.0254% | $52.33 | 0 | 7 | |
| COWARD D SCOTT | director | 44644 0.0241% | $52.33 | 0 | 43 | |
| LEVANGIE DANIEL J | director | 22975 0.0124% | $52.33 | 1 | 3 | +50.94% |
| ORVILLE JACOB A | General Manager, Screening | 14440 0.0078% | $52.33 | 0 | 18 | |
| Baranick Brian | EVP, GM, Precision Oncology | 12758 0.0069% | $52.33 | 0 | 13 | |
| Elliott Jeffrey Thomas | Chief Financial Officer | 11795 0.0064% | $52.33 | 0 | 33 | |
| Herriott James | SVP, General Counsel & Sec | 9866 0.0053% | $52.33 | 0 | 12 | |
| ARORA MANEESH | COO | 645089 0.3486% | $52.33 | 3 | 24 | +31.72% |
| CRAWFORD SALLY | director | 212341 0.1147% | $52.33 | 0 | 4 | |
| THOMPSON DAVID | director | 136379 0.0737% | $52.33 | 3 | 0 | +87.45% |
| Sterling Lionel | director | 121247 0.0655% | $52.33 | 4 | 0 | +34.27% |
| Zanotti Katherine S | director | 64629 0.0349% | $52.33 | 2 | 12 | +89.67% |
| LIDGARD GRAHAM PETER | Chief Science Officer | 38367 0.0207% | $52.33 | 0 | 46 | |
| Fallon John A. | director | 33767 0.0182% | $52.33 | 0 | 1 | |
| SHUBER ANTHONY P | Chief Tech Officer & Sen. V.P. | 31000 0.0167% | $52.33 | 0 | 1 | |
| Stenhouse Mark | President, Cologuard | 29571 0.016% | $52.33 | 0 | 3 | |
| Carey Thomas D. | director | 21872 0.0118% | $52.33 | 1 | 6 | +34.46% |
| Megan William J. | SVP, Finance & PFO | 12522 0.0068% | $52.33 | 1 | 0 | +88.75% |
| Johnson Scott C. | SVP - Research and Development | 12311 0.0067% | $52.33 | 0 | 2 | |
| Cole G Bradley | General Manager - Diagnostics | 10194 0.0055% | $52.33 | 0 | 3 | |
| WYZGA MICHAEL S | director | 2558 0.0014% | $52.33 | 0 | 5 | |
| Hoof Torsten | General Manager, International | 2017 0.0011% | $52.33 | 0 | 2 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| The Vanguard Group | $1.23B | 9.61 | 17.74M | +1.03% | +$12.45M | 0.02 | |
| Capital World Investors | $899.53M | 7.06 | 13.03M | +74.41% | +$383.78M | 0.15 | |
| JPMorgan Chase | $855.27M | 6.71 | 12.38M | -25.8% | -$297.39M | 0.08 | |
| BlackRock | $785.63M | 6.17 | 11.38M | +2.92% | +$22.31M | 0.02 | |
| Wellington Management Company | $737.55M | 5.79 | 10.68M | +3.88% | +$27.56M | 0.13 | |
| State Street | $351.77M | 2.76 | 5.09M | +1.45% | +$5.03M | 0.01 | |
| ARK Investment Management LLC | $225.66M | 1.77 | 3.27M | -45.84% | -$190.97M | 0.78 | |
| Artisan Partners | $214.91M | 1.69 | 3.11M | -30.39% | -$93.81M | 0.32 | |
| Geode Capital Management | $204.74M | 1.61 | 2.97M | +3.11% | +$6.18M | 0.02 | |
| Millennium Management LLC | $203.49M | 1.6 | 2.95M | +1,207.09% | +$187.92M | 0.13 | |
| T Rowe Price Investment Management Inc | $202.93M | 1.59 | 2.94M | -0.43% | -$883,968.23 | 0.12 | |
| Holocene Advisors, LP | $172.54M | 1.35 | 2.5M | +560.33% | +$146.41M | 0.64 | |
| Ameriprise Financial | $156.07M | 1.23 | 2.26M | -8.94% | -$15.33M | 0.04 | |
| Champlain Investment Partners, LLC | $155.95M | 1.22 | 2.26M | +175.32% | +$99.31M | 0.89 | |
| Citadel Advisors LLC | $141.86M | 1.11 | 2.05M | -25.02% | -$47.34M | 0.08 | |
| Sumitomo Mitsui Trust Holdings | $136.3M | 1.07 | 1.97M | -10.67% | -$16.27M | 0.09 | |
| Point72 Asset Management | $136.03M | 1.07 | 1.97M | +52.79% | +$47M | 0.2 | |
| Ensign Peak Advisors Inc | $125.4M | 0.98 | 1.82M | +19.07% | +$20.09M | 0.22 | |
| Baillie Gifford Co | $117.54M | 0.92 | 1.7M | -54.82% | -$142.61M | 0.09 | |
| Nikko Asset Management Americas Inc | $105.52M | 0.83 | 1.53M | -13.13% | -$15.95M | 0.79 | |
| Zevenbergen Capital Investments LLC (ZCI) | $94.02M | 0.74 | 1.36M | +20.5% | +$15.99M | 2 | |
| T. Rowe Price | $92.9M | 0.73 | 1.35M | -6.88% | -$6.87M | 0.01 | |
| Fidelity Investments | $92.19M | 0.72 | 1.33M | +51.23% | +$31.23M | 0.01 | |
| Ubs Asset Management Americas Inc | $90.78M | 0.71 | 1.31M | +68.34% | +$36.85M | 0.03 | |
| Morgan Stanley | $90.15M | 0.71 | 1.31M | -4.28% | -$4.03M | 0.01 | |
| Bank of America | $89.44M | 0.7 | 1.3M | +8.29% | +$6.85M | 0.01 | |
| Charles Schwab | $82.21M | 0.65 | 1.19M | +1.92% | +$1.55M | 0.02 | |
| C Worldwide Group Holding A S | $78.59M | 0.62 | 1.14M | +80.01% | +$34.93M | 0.9 | |
| Bellevue Group | $78.63M | 0.62 | 1.14M | +8.66% | +$6.27M | 1.21 | |
| Legal & General | $76.91M | 0.6 | 1.11M | -2.01% | -$1.58M | 0.02 | |
| Eventide Asset Management | $74.91M | 0.59 | 1.08M | +0.13% | +$97,305.54 | 1.21 | |
| Spyglass Capital Management LLC | $73.25M | 0.58 | 1.06M | +39.82% | +$20.86M | 4.88 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $73.19M | 0.57 | 1.06M | +3.95% | +$2.78M | 1.91 | |
| Northern Trust | $68.31M | 0.54 | 989,211 | -8.53% | -$6.37M | 0.01 | |
| Renaissance Technologies | $68.22M | 0.54 | 987,904 | +3.89% | +$2.56M | 0.11 | |
| Credit Suisse | $67.47M | 0.53 | 976,932 | -1.28% | -$877,890.72 | 0.06 | |
| Goldman Sachs | $65.64M | 0.52 | 950,537 | +3.8% | +$2.4M | 0.01 | |
| Nuveen | $63.99M | 0.5 | 926,554 | -1.04% | -$670,848.84 | 0.02 | |
| Dimensional Fund Advisors | $61.77M | 0.49 | 894,488 | +28.6% | +$13.74M | 0.02 | |
| First Trust | $58.77M | 0.46 | 850,956 | -4.67% | -$2.88M | 0.06 | |
| Citigroup | $53.2M | 0.42 | 770,384 | +325.38% | +$40.7M | 0.04 | |
| Balyasny Asset Management Llc | $52.54M | 0.41 | 760,845 | +11,565.82% | +$52.09M | 0.14 | |
| BNY Mellon | $52.03M | 0.41 | 753,358 | -10.89% | -$6.36M | 0.01 | |
| Armistice Capital Llc | $50.46M | 0.4 | 730,648 | -5.33% | -$2.84M | 0.16 | |
| Iron Triangle Partners LP | $48.34M | 0.38 | 700,000 | New | +$48.34M | 5.14 | |
| Frontier Capital Management Co | $45.31M | 0.36 | 656,056 | +12.68% | +$5.1M | 0.42 | |
| PEREGRINE CAPITAL MANAGEMENT INC | $45.21M | 0.36 | 654,593 | -0.62% | -$283,836.60 | 1.3 | |
| Casdin Capital | $44.89M | 0.35 | 650,000 | +54.76% | +$15.88M | 2.22 | |
| JENNISON ASSOCIATES LLC | $43.76M | 0.34 | 633,629 | -53.44% | -$50.23M | 0.03 | |
| Deutsche Bank | $41.05M | 0.32 | 594,423 | +3.37% | +$1.34M | 0.02 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.